Patent US3765213A successfully refreshed from Google Patents.
← Back to Patent Explorer
US5567415A Expired / Lapsed US ⏱️ 0.0 years remaining

Ultrasound contrast agents and methods for their manufacture and use

Assignee: University of Nebraska System
•
Filing: 1994-06-01
•
Granted: 1996-10-22
•
Expires: 2014-06-01
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract This invention relates to a new ultrasound contrast agent of the type which relies on microbubbles for echogenicity. The improvement comprises enhancing the internal atmosphere of the microbubbles with an amount of perfluoropropane which is effective for visually detecting myocardial uptake upon echocardiogram following peripheral intravenous injection of said agent into a host. The contrast agent of this invention is unique in that it makes possible the non-invasive visual detection of myocardial uptake. In addition, the contrast agent of this invention makes feasible safe and consistent, non-invasive methods for visually assessing, qualitatively or quantitatively, not only myocardial perfusion, but renal and hepatic perfusion, and for detecting severity of coronary arterial stenosis. the invnetion also relates to a method of ultrasonic imaging for use in medical procedures, comprising the steps of injecting perfluoropropane-containing microbubbles into a mammal to thereby alter the acoustic properties of a predetermined area, and ultrasonically scanning an area including said predetermined area so as to obtain an image of said predetermined area.

Inventors

  • 👤 Thomas R. Porter

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-09 02:52
CPC Classifications
A; A61; A61K; A61K49/00; A61K49/22; A61K49/222; A61K49/223

Claims Analysis

Total Claims: 13
Claim 1
Independent Claim 54 words
A pharmaceutically acceptable ultrasound contrast agent which relies on microbubbles for echogenicity, comprising: microbubbles with an internal atmosphere enhanced with an amount of perfluoropropane gas which is effective for visually detecting myocardial contrast, said microbubbles formed from a solution of dextrose and albumin wherein said dextrose comprises about 3.75% by weight of said solution.
Claim 2
Dependent Claim 54 words
A pharmaceutically acceptable ultrasound contrast agent which relies on microbubbles for echogenicity, comprising: microbubbles with an internal atmosphere enhanced with an amount of perfluoropropane gas which is effective for visually detecting myocardial contrast, said microbubbles formed from a solution of dextrose and albumin wherein said dextrose comprises about 3.75% by weight of said solution.
Claim 3
Dependent Claim 50 words
An ultrasound contrast agent comprising: a sonicated aqueous albumin-dextrose solution wherein said dextrose comprises less than about 40% by weight of said solution and microbubbles with a perfluorocarbon gaseous content which is effective for visually detecting myocardial perfusion upon echocardiogram following peripheral intravenous injection of said agent into a host.
Claim 4
Dependent Claim 50 words
An ultrasound contrast agent comprising: a sonicated aqueous albumin-dextrose solution wherein said dextrose comprises less than about 40% by weight of said solution and microbubbles with a perfluorocarbon gaseous content which is effective for visually detecting myocardial perfusion upon echocardiogram following peripheral intravenous injection of said agent into a host.
Claim 5
Independent Claim 67 words
A method of ultrasonic imaging for use in medical procedures, comprising the steps of: (a) injecting perfluoropropane-containing microbubbles in an albumin dextrose solution having less than 40% by weight of said solution comprising dextrose, into a mammal to thereby alter the acoustic properties of a predetermined area, and b) ultrasonically scanning an area including said predetermined area so as to obtain an image of said predetermined area.
Claim 6
Independent Claim 67 words
A method of ultrasonic imaging for use in medical procedures, comprising the steps of: (a) injecting perfluoropropane-containing microbubbles in an albumin dextrose solution having less than 40% by weight of said solution comprising dextrose, into a mammal to thereby alter the acoustic properties of a predetermined area, and b) ultrasonically scanning an area including said predetermined area so as to obtain an image of said predetermined area.
Claim 7
Independent Claim 59 words
A method of making an ultrasonic contrast agent for echocardiographic imaging comprising the steps of: forming an aqueous protein solution containing 3.75% by weight of dextrose, and thereafter subjecting said solution to high frequency sonication while exposing said solution to perfluoropropane gas, said sonication forming stabilized microbubbles of relatively uniform size, containing said perfluoropropane, and capable of transpulmonary passage.
Claim 8
Independent Claim 59 words
A method of making an ultrasonic contrast agent for echocardiographic imaging comprising the steps of: forming an aqueous protein solution containing 3.75% by weight of dextrose, and thereafter subjecting said solution to high frequency sonication while exposing said solution to perfluoropropane gas, said sonication forming stabilized microbubbles of relatively uniform size, containing said perfluoropropane, and capable of transpulmonary passage.
Claim 9
Independent Claim 75 words
A method for myocardial, renal or heptic opacification comprising the following steps: mixing human serum albumin with a solution comprising an aqueous monosaccharide in a ratio of 1:3 to 1:7 respectively to form a solution; sonicating said solution for at least 80 seconds to form microbubbles approximately 3 to 5 microns in diameter, thereby forming an echo contrast agent; intravenously injecting said solution into an animal subject; and detecting the image produced by ultrasound imaging.
Claim 10
Independent Claim 75 words
A method for myocardial, renal or heptic opacification comprising the following steps: mixing human serum albumin with a solution comprising an aqueous monosaccharide in a ratio of 1:3 to 1:7 respectively to form a solution; sonicating said solution for at least 80 seconds to form microbubbles approximately 3 to 5 microns in diameter, thereby forming an echo contrast agent; intravenously injecting said solution into an animal subject; and detecting the image produced by ultrasound imaging.
Claim 11
Dependent Claim 36 words
The contrast agent of claim 2 wherein said mixture comprises between about a 2-fold to about an 8-fold dilution of said human serum albumin with about a 5% to about a 50% solution of aqueous dextrose.
Claim 12
Dependent Claim 17 words
The contrast agent of claim 2 wherein said mixture comprises about a 7-fold dilution of 50% dextrose.
Claim 13
Dependent Claim 17 words
The contrast agent of claim 2 wherein said mixture comprises about a 3-fold dilution of 5% dextrose.

References Cited (Backward Citations)

WO1992005806A1 Cited
US5413774A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1999-10-22 2000-04-22 2000-10-22 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 2003-10-22 2004-04-22 2004-10-22 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2007-10-22 2008-04-22 2008-10-22 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag